Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | SP4 | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-11 |
mRNA | HDAC2 | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-11 |
mRNA | BEND3 | CTRPv2 | pan-cancer | AAC | 0.23 | 3e-11 |
mRNA | RTFDC1 | CTRPv2 | pan-cancer | AAC | -0.23 | 3e-11 |
mRNA | SFPQ | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-11 |
mRNA | IPO9 | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-11 |
mRNA | PHIP | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-11 |
mRNA | ICA1L | CTRPv2 | pan-cancer | AAC | 0.21 | 9e-11 |
mRNA | YPEL1 | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-10 |
mRNA | IRAK1BP1 | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-10 |